Target validation of G-protein coupled receptors.
G-protein coupled receptors (GPCRs) represent possibly the most important target class of proteins for drug discovery. Over 30% of clinically marketed drugs are active at this receptor family. These drugs exhibit their activity at <10% of all known GPCRs. A major challenge for the pharmaceutical industry is to associate the many novel GPCRs with disease to identify the drugs of the future. This process consists of a collection of experimental paradigms that together can be loosely labelled 'target validation'.
Wise
Alan
A
Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK SG1 2NY.
Gearing
Katy
K
Rees
Stephen
S
D000818:Animals; D003198:Computer Simulation; D019204:GTP-Binding Proteins / Q000502:physiology*; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D008954:Models, Biological; D009965:Orphan Drug Production; D010600:Pharmacology; D011955:Receptors, Drug / Q000187:drug effects*
D011955:Receptors, Drug; D019204:GTP-Binding Proteins